MedTrace Logo

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

NCT03510416 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-04-27

No results posted yet for this study

Summary

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .

Conditions

  • Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization

Interventions

DRUG

Apatinib

apatinib is a kind of Inhibitor of VEGFR-2

RADIATION

TACE

Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • zhiping Yan, MD · Department of Interventional Radiology, Zhongshan Hospital, Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-06-30
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03510416 on ClinicalTrials.gov